2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
This guideline cites 9 of the 199 landmark trials in our Cardiology register.
- Issued by
- ESC
- Year
- 2021
- Source
- Visseren FLJ, Mach F, et al. Eur Heart J. 2021;42(34):3227–3337.doi 10.1093/eurheartj/ehab484
The 2021 ESC prevention guideline introduced SCORE2/SCORE2-OP risk charts and a stepwise, personalised intensification of lipid, blood-pressure, antithrombotic and cardiometabolic therapy. Its evidence spans several register domains — the landmark trials are grouped by risk factor below.
Lipid lowering3
- 2018ODYSSEY OUTCOMESCardiology · Lipids · PCSK9 inhibitorIn 18,924 patients with recent acute coronary syndrome on high-intensity statin, alirocumab reduced major adverse cardiovascular events compared with placebo (HR 0.85, 95% CI 0.78-0.93).HR 0.8595% CI 0.78-0.93Read →
- 2017FOURIERCardiology · Lipids · PCSK9iIn 27,564 patients with ASCVD on statins, evolocumab reduced CV death, MI, stroke, hosp UA or revasc compared with placebo.HR 0.8595% CI 0.79-0.92Read →
- 2015IMPROVE-ITCardiology · Lipids · Non-statin LDLIn 18,144 patients post-ACS, ezetimibe added to simvastatin further reduced CV death, MI, UA, revasc or stroke compared with simvastatin alone.HR 0.94Read →
Blood-pressure lowering2
- 2015SPRINT CoreCardiology · HTN · BP targetIn 9,361 high-risk non-diabetic hypertensive adults, intensive BP control to SBP < 120 mm Hg reduced CV events and all-cause mortality compared with standard control to SBP < 140 mm Hg.HR 0.75Read →
- 2008ACCOMPLISHCardiology · HTN · Drug classIn 11,506 high-risk patients with hypertension, an ACE inhibitor plus amlodipine reduced cardiovascular events compared with an ACE inhibitor plus hydrochlorothiazide.HR 0.8Read →
Antithrombotic & RAAS therapy2
- 2017COMPASSCardiology · Thrombosis · Chronic atherosclerosisIn 27,395 patients with stable coronary or peripheral artery disease, low-dose rivaroxaban plus aspirin reduced cardiovascular death, stroke or MI compared with aspirin alone.HR 0.76Read →
- 2000HOPECardiology · Coronary · ACE inhibitorIn 9,297 high-risk patients with vascular disease or diabetes and preserved LV function, ramipril reduced MI, stroke, or cardiovascular death compared with placebo.RR 0.7895% CI 0.70-0.86Read →
Cardiometabolic prevention2
- 2016LEADERCardiology · Cardiometabolic · GLP-1 RAIn 9,340 patients with type 2 diabetes at high cardiovascular risk, liraglutide reduced major adverse cardiovascular events compared with placebo.HR 0.87Read →
- 2015EMPA-REG OUTCOME CoreCardiology · Cardiometabolic · SGLT2 inhibitorsIn 7,020 patients with type 2 diabetes and cardiovascular disease, empagliflozin reduced cardiovascular death compared with placebo.HR 0.86Read →
Published since the guideline2
- 2023CLEAR OutcomesCardiology · Lipids · Non-statin LDLIn 13,970 statin-intolerant patients, bempedoic acid reduced major adverse cardiovascular events compared with placebo.HR 0.87Read →
- 2023SELECT CoreCardiology · Cardiometabolic · GLP-1 RAIn 17,604 patients with obesity and cardiovascular disease but without diabetes, semaglutide reduced major adverse cardiovascular events compared with placebo.HR 0.8Read →
Cited landmark trials not yet in the register3
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.